5 completed, 3 recruiting, 3 unknown, 1 active not recruiting. 14 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 5, Recruiting 3, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Epidermolysis Bullosa Simplex: new trials by email Literature Review of Epidermolysis Bullosa Simplex trials Research Report on Epidermolysis Bullosa Simplex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa ENERGI-F703EB Cream, Matched vehicle cream - Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa | Phase 2 | Recruiting | Energenesis Biomedical Co., Ltd. | 24 | 2026-10-08 | 2026-10-05 |
| Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex Filsuvez - Epidermolysis Bullosa Simplex | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-10-01 | 2026-08-10 |
| A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex 5% TolaSure Topical Gel, Topical Placebo Gel - Epidermolysis Bullosa Simplex | Phase 2 | Recruiting | BioMendics, LLC | 40 | 2025-09-11 | 2026-08-13 |
| A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized Apremilast treatment - Epidermolysis Bullosa Simplex, Genodermatosis | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2024-08-06 | 2025-02-24 |
| An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) AC-203, Vehicle - Generalized Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Active not recruiting | TWi Biotechnology, Inc. | 80 | 2024-04-04 | 2026-07-09 |
| A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses deucravacitinib - Epidermolysis Bullosa Simplex, Ichthyosis | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2024-03-18 | 2026-10-16 |
| INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa INM-755 (cannabinol) cream, Vehicle Cream - Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional | Phase 2 | Completed | InMed Pharmaceuticals Inc. | 19 | 2021-12-28 | 2023-07-03 |
| Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Botulinic toxin, Placebo - Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 18 | 2018-06-14 | 2026-09-21 |
| Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex diacerein 1% ointment - Epidermolysis Bullosa, Epidermolysis Bullosa Simplex | Phase 2 | Completed | Castle Creek Pharmaceuticals, LLC | 51 | 2017-12-01 | 2020-09-16 |
| Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) diacerein 1% ointment, A placebo ointment - Epidermolysis Bullosa Simplex | Phase 2 | Terminated | Castle Creek Pharmaceuticals, LLC | 54 | 2017-06-01 | 2019-11-05 |
| Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Sirolimus, 2%, Vehicle - Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner | Phase 2 | Completed | Stanford University | 8 | 2016-05-01 | 2022-03-09 |
| Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Sirolimus 2%, Vehicle - Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner | Phase 2 | Unknown | Premier Specialists, Australia | 8 | 2016-05-01 | 2017-10-24 |
| Diacerin for the Treatment of Epidermolysis Bullosa Simplex Diacerin cream - Epidermolysis Bullosa Simplex | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 50 | 2015-06-01 | 2015-06-12 |
| Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Dysport® (Botulinumtoxin A (Btx A)), Placebo - Epidermolysis Bullosa Simplex | Phase 2 | Unknown | Uppsala University | 40 | 2009-05-01 | 2011-03-09 |
Epidermolysis Bullosa (3) · Epidermolysis Bullosa Dystrophica (2) · Epidermolysis Bullosa, Junctional (2) · Skin Diseases, Genetic (2) · Blister (1) · Ichthyosis (1) · Poikiloderma of Kindler (1) · Skin Abnormalities (1) · Skin Diseases (1)
Congenital Abnormalities (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (14) · Skin Diseases, Vesiculobullous (14) · Skin and Connective Tissue Diseases (14) · Skin Abnormalities (13) · Skin Diseases (13) · Skin Diseases, Genetic (12) · Epidermolysis Bullosa (11) · Collagen Diseases (2) · Connective Tissue Diseases (2) · Infant, Newborn, Diseases (1) · Keratosis (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
diacerein (3) · Ointments (2) · abobotulinumtoxinA (2) · Cannabinol (1) · Drugs, Investigational (1) · Sirolimus (1) · deucravacitinib (1)
Castle Creek Pharmaceuticals, LLC (2) · Centre Hospitalier Universitaire de Nice (2) · Stanford University (2) · BioMendics, LLC (1) · Energenesis Biomedical Co., Ltd. (1) · InMed Pharmaceuticals Inc. (1) · Premier Specialists, Australia (1) · TWi Biotechnology, Inc. (1) · Tel-Aviv Sourasky Medical Center (1) · University Hospital, Toulouse (1) · Uppsala University (1)
United States (6) · France (5) · Australia (3) · Israel (3) · Austria (2) · Germany (2) · Greece (2) · Italy (2) · Taiwan (2) · United Kingdom (2) · Belgium (1) · China (1) · India (1) · Ireland (1) · Malaysia (1)
Mary Spellman, MD (2) · Alexandra DJ Mancini, MSc (1) · Carl Swartling (1) · Christine Chiaverini (1) · Dedee F Murrell, MD (1) · Eli Sprecher, Prof. (1) · Joyce M Teng, MD, PhD (1) · Joyce Teng, MD, PhD, FAAD (1) · Juliette Mazereeuw-Hautier, MD (1)
2017 (1), 2023 (1)